[article] 
inJournal of Autism and Developmental Disorders > 41-11 (November 2011) . - p.1515-1522

Titre :	Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Faraz FARZIN, Auteur ; Felicia SCAGGS, Auteur ; Crystal HERVEY, Auteur ; Elizabeth BERRY-KRAVIS, Auteur ; David HESSL, Auteur
Année de publication :	2011
Article en page(s) :	p.1515-1522
Langues :	Anglais (eng)
Mots-clés :	Face processing  Gaze  Fixation  FMR1 gene  fragile X syndrome  Outcome measure  Pharmacotherapy
Index. décimale :	PER Périodiques
Résumé :	Recent insight into the underlying molecular and cellular mechanisms of fragile X syndrome (FXS) has led to the proposal and development of new pharmaceutical treatment strategies, and the initiation of clinical trials aimed at correcting core symptoms of the developmental disorder. Consequently, there is an urgent and critical need for outcome measures that are valid for quantifying specific symptoms of FXS and that are consistent across time. We used eye tracking to evaluate test–retest reliability of gaze and pupillometry measures in individuals with FXS and we demonstrate that these measures are viable options for assessing treatment-specific outcomes related to a core behavioral feature of the disorder.
En ligne :	http://dx.doi.org/10.1007/s10803-011-1176-2
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=147

[article] Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome [Texte imprimé et/ou numérique] / Faraz FARZIN, Auteur ; Felicia SCAGGS, Auteur ; Crystal HERVEY, Auteur ; Elizabeth BERRY-KRAVIS, Auteur ; David HESSL, Auteur . - 2011 . - p.1515-1522.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 41-11 (November 2011) . - p.1515-1522

Mots-clés :	Face processing  Gaze  Fixation  FMR1 gene  fragile X syndrome  Outcome measure  Pharmacotherapy
Index. décimale :	PER Périodiques
Résumé :	Recent insight into the underlying molecular and cellular mechanisms of fragile X syndrome (FXS) has led to the proposal and development of new pharmaceutical treatment strategies, and the initiation of clinical trials aimed at correcting core symptoms of the developmental disorder. Consequently, there is an urgent and critical need for outcome measures that are valid for quantifying specific symptoms of FXS and that are consistent across time. We used eye tracking to evaluate test–retest reliability of gaze and pupillometry measures in individuals with FXS and we demonstrate that these measures are viable options for assessing treatment-specific outcomes related to a core behavioral feature of the disorder.
En ligne :	http://dx.doi.org/10.1007/s10803-011-1176-2
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=147